- Taking a GLP-1 Medication? Here’s Tips to Holiday Eating
- Bird Flu Virus in Canadian Teen Shows Mutations That Could Help It Spread Among Humans
- Flu, COVID Vaccination Rates Remain Low as Winter Nears
- ’10 Americas:’ Health Disparities Mean Life Expectancy Varies Across U.S.
- Short-Term Hormone Therapy for Menopause Won’t Harm Women’s Brains
- Could a Vitamin Be Effective Treatment for COPD?
- Woman Receives World’s First Robotic Double-Lung Transplant
- Flavored Vapes Behind Big Surge in U.S. E-Cigarette Sales
- Reading Beyond Headline Rare For Most on Social Media, Study Finds
- Meds Like Ozempic Are Causing Folks to Waste More Food
Health Highlights: June 16, 2017
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
New EpiPen Competitor Approved by FDA
A new competitor for EpiPen has been approved by the U.S. Food and Drug Administration.
The emergency injection device to treat life-threatening allergic reactions is called Symjepi and is made by Adamis Pharmaceuticals Corp., the Associated Press reported.
Symjepi is meant to be a “low-cost alternative” to EpiPen and similar products, and Adamis wants to sell it for less than generic EpiPens, according to company spokesman Mark Flather.
EpiPens have soared in price in recent years, prompting concern from doctors and patients alike.
An exact price has not been set for Symjepi, which will be sold in pairs like EpiPen, the AP reported.
Copyright © 2024 HealthDay. All rights reserved.